TITLE

The analysis by Manuel and colleagues creates controversy with headlines, not data

AUTHOR(S)
Genest, Jacques; McPherson, Ruth; Frohlich, Jiri; Fodor, George
PUB. DATE
April 2005
SOURCE
CMAJ: Canadian Medical Association Journal;4/12/2005, Vol. 172 Issue 8, p1033
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Comments on the main point of contention in the analysis by Douglas G. Manuel and colleagues which centres on the number of people at low risk who might be prescribed statins according to revised 2003 recommendations. Significance of the INTERHEART study; Limitations of the Canadian Heart Health Survey dataset; Criticism on how Manuel and colleagues estimate the magnitude of the benefit of statin therapy.
ACCESSION #
16624479

 

Related Articles

  • GPs divided over statins for healthy patients. Tanday, Sanjay // GP: General Practitioner;3/13/2009, p15 

    The article reports on the survey which examines the therapeutic use of statins in healthy people in Great Britain. It showed that physicians are split over the benefits of giving statins to healthy people. It indicated that 48% of the total respondents believe that the use of statins in healthy...

  • Cardiologists like statins-more than patients do. Mitka, Mike; Mitka, M // JAMA: Journal of the American Medical Association;12/12/2001, Vol. 286 Issue 22, p2799 

    Reports the results of a study which showed that use of statin therapy reduces the risk of major vascular events in patients at high risk for heart disease. Details of the study; Evidence that statin therapy reduced risk in patients for whom there was uncertainty about the effectiveness of...

  • Statins diabetes hope.  // Pulse;6/7/2004, Vol. 64 Issue 23, p1 

    Discusses the implications of a trial investigating the benefits for statins in diabetic patients with normal cholesterol levels. Demand for statins; Cardiovascular treatment; Prescription.

  • EU go-ahead for GSK vaccine.  // Pharmaceutical Technology Europe;Nov2007, Vol. 19 Issue 11, p10 

    The author reflects on the effect of statins on the promotion of health among people. He points out that people claim the effectivity of statins for it promotes cholesterol dropouts without the detected risks. Further, he stresses that such medication has complications in the end if there is...

  • More Money to Fight Cholesterol, MS. Gopal, Kevin // Pharmaceutical Executive;Apr2002, Vol. 22 Issue 4, p28 

    Focuses on the decision of Pharmac, a drug-funding agency in New Zealand, to widen access to the cholesterol-lowering medicines. Increase in the number of patients treated with statins in the country; Significance of the use of statins to treat people who are at risk of heart disease; Details of...

  • Ezetimibe added to ongoing statin therapy reduced LDL cholesterol in primary hypercholesterolemia. Bronson, David L. // ACP Journal Club;Jul/Aug2003, Vol. 139 Issue 1, p8 

    Presents information on a study which added ezetimibe, a lipid-lowering agent, to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Main outcome measures; Efficacy of ezetimibe; Safety and efficacy of statins.

  • Statins reduce post-MI mortality.  // Cortlandt Forum;10/25/2005, Vol. 18 Issue 10, p15 

    Reports on the study which found the potential of statins in reducing a myocardial infarction (MI) patient's chances of dying during hospitalization. Addition of clopidogrel would protect the worsening of MI conditions; Association of statins with lower incidence of cardiac arrest; Short- and...

  • Life after statin patent expiries. Kidd, Jane // Nature Reviews Drug Discovery;Oct2006, Vol. 5 Issue 10, p813 

    The article offers news briefs related to statins. Statins differ in potency, but many patients require LDL reductions of only 30–40%, which is achievable with all statins. Before the statins became the treatment of choice for high cholesterol, the hypolipidaemics were used routinely,...

  • Statin monotherapy 'is best in atherosclerosis'. Baines, Emma // GP: General Practitioner;9/13/2004, p5 

    The article reports that, combining a statin with ezetimibe has no advantage over statins alone in treating patients with atherosclerosis, according to a review of existing research. Researchers looked at six studies comparing LDL reduction with a combination of a statin and ezetimibe versus a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics